FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322304890> ?p ?o ?g. }

• W2322304890 endingPage "340" @default.
• W2322304890 startingPage "336" @default.
• W2322304890 abstract "Combining antineoplastic analogues may increase efficacy by increasing the serum and intracellular concentration of the cytotoxic moiety shared by the analogues. Topotecan and irinotecan are two camptothecan analogues that are active in different human tumors (topotecan in ovary; irinotecan in colon) and in different experimental tumor systems. These data suggest that different mechanisms of drug resistance may be operative for the two agents, and if incomplete cross-resistance exists between analogues, concomitant administration may be advantageous. The objectives of this phase I study were 1) to determine in a phase trial design whether topotecan and irinotecan administered concomitantly on a weekly schedule can be delivered at the same dose intensity as that of single-agent topotecan or irinotecan delivery; and 2) to determine whether hematologic and/or nonhematologic toxicity is increased with topotecan and irinotecan administered together as a prelude to a possible phase II trial in responsive tumor categories. Irinotecan was administered for 30 to 45 minutes weekly × 4 at four dose levels: 50, 75, 100, and 125 mg/m2/wk. Topotecan was administered for 30 minutes (after irinotecan administration) at two dose levels within each of the irinotecan dose levels (1.0 and 1.5 mg/m2). Concomitant single-dose granulocytemacrophage colony-stimulating factor (G-CSF) was used for leukocyte counts between 1,000 cells/mm3 and 3,500 cells/mm3 to maintain schedule. Maximum tolerated dosage (MTD) for the topotecan and irinotecan combination was defined as that which permitted 4 weeks of topotecan and irinotecan administration with G-CSF at or near the dose intensity reported for each single agent. Twenty-one patients received 32 4-week cycles. Dose-limiting toxicity was hematologic with grade IV leukopenia and neutropenia occurring at all dose levels. There was no apparent increase in the diarrhea syndrome associated with irinotecan. The MTD for irinotecan (at 125 mg/m2/wk) is the same MTD as with single-agent irinotecan use. The MTD for concomitant topotecan (1.5 mg/m2/wk) is 60% of the single-agent topotecan dose for the 5-day topotecan schedule (at 2.5 mg/m2/wk) but only 30% of the single-agent topotecan dose for the weekly schedule (5 mg/m2/wk). The topoisomerase I inhibitor dose is increased minimally when the analogues are administered concomitantly on a weekly schedule. Comparative trials of single-agent topotecan and irinotecan versus the combination of topotecan and irinotecan would be necessary to provide the proof of principle that combining analogues can increase therapeutic effectiveness." @default.
• W2322304890 created "2016-06-24" @default.
• W2322304890 creator A5004376520 @default.
• W2322304890 date "2001-08-01" @default.
• W2322304890 modified "2023-10-18" @default.
• W2322304890 title "Phase I Clinical Trial of Weekly Combined Topotecan and Irinotecan" @default.
• W2322304890 cites W1832060645 @default.
• W2322304890 cites W1967315421 @default.
• W2322304890 cites W1984351265 @default.
• W2322304890 cites W2006824814 @default.
• W2322304890 cites W2069984871 @default.
• W2322304890 cites W2082817995 @default.
• W2322304890 cites W2089338192 @default.
• W2322304890 cites W2096122707 @default.
• W2322304890 cites W2113067724 @default.
• W2322304890 cites W2120828641 @default.
• W2322304890 cites W2885190381 @default.
• W2322304890 doi "https://doi.org/10.1097/00000421-200108000-00003" @default.
• W2322304890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11474256" @default.
• W2322304890 hasPublicationYear "2001" @default.
• W2322304890 type Work @default.
• W2322304890 sameAs 2322304890 @default.
• W2322304890 citedByCount "13" @default.
• W2322304890 countsByYear W23223048902014 @default.
• W2322304890 countsByYear W23223048902017 @default.
• W2322304890 crossrefType "journal-article" @default.
• W2322304890 hasAuthorship W2322304890A5004376520 @default.
• W2322304890 hasConcept C121608353 @default.
• W2322304890 hasConcept C126322002 @default.
• W2322304890 hasConcept C143998085 @default.
• W2322304890 hasConcept C2776694085 @default.
• W2322304890 hasConcept C2779384505 @default.
• W2322304890 hasConcept C2779682216 @default.
• W2322304890 hasConcept C2780259306 @default.
• W2322304890 hasConcept C2780508388 @default.
• W2322304890 hasConcept C2781209748 @default.
• W2322304890 hasConcept C526805850 @default.
• W2322304890 hasConcept C55493867 @default.
• W2322304890 hasConcept C71924100 @default.
• W2322304890 hasConcept C86803240 @default.
• W2322304890 hasConcept C98274493 @default.
• W2322304890 hasConceptScore W2322304890C121608353 @default.
• W2322304890 hasConceptScore W2322304890C126322002 @default.
• W2322304890 hasConceptScore W2322304890C143998085 @default.
• W2322304890 hasConceptScore W2322304890C2776694085 @default.
• W2322304890 hasConceptScore W2322304890C2779384505 @default.
• W2322304890 hasConceptScore W2322304890C2779682216 @default.
• W2322304890 hasConceptScore W2322304890C2780259306 @default.
• W2322304890 hasConceptScore W2322304890C2780508388 @default.
• W2322304890 hasConceptScore W2322304890C2781209748 @default.
• W2322304890 hasConceptScore W2322304890C526805850 @default.
• W2322304890 hasConceptScore W2322304890C55493867 @default.
• W2322304890 hasConceptScore W2322304890C71924100 @default.
• W2322304890 hasConceptScore W2322304890C86803240 @default.
• W2322304890 hasConceptScore W2322304890C98274493 @default.
• W2322304890 hasIssue "4" @default.
• W2322304890 hasLocation W23223048901 @default.
• W2322304890 hasLocation W23223048902 @default.
• W2322304890 hasOpenAccess W2322304890 @default.
• W2322304890 hasPrimaryLocation W23223048901 @default.
• W2322304890 hasRelatedWork W1972477507 @default.
• W2322304890 hasRelatedWork W2013600522 @default.
• W2322304890 hasRelatedWork W2022541271 @default.
• W2322304890 hasRelatedWork W2028066947 @default.
• W2322304890 hasRelatedWork W2072106056 @default.
• W2322304890 hasRelatedWork W2128774674 @default.
• W2322304890 hasRelatedWork W2215145163 @default.
• W2322304890 hasRelatedWork W2322304890 @default.
• W2322304890 hasRelatedWork W2740645528 @default.
• W2322304890 hasRelatedWork W4225948320 @default.
• W2322304890 hasVolume "24" @default.
• W2322304890 isParatext "false" @default.
• W2322304890 isRetracted "false" @default.
• W2322304890 magId "2322304890" @default.
• W2322304890 workType "article" @default.